Charles Sang

Adaptive Biotechnologies has appointed Charles Sang as senior vice president of diagnostics. He will be taking over from Tom Willis, who will be transitioning to an advisory role and will remain an active member on the company's board. Most recently, Sang served as the vice president of global diagnostics for nanostring technologies and led their North American and global commercial efforts for a new company's breast cancer prognostic gene signature assay.